MaxCyte Inc.

06/16/2026 | Press release | Distributed by Public on 06/16/2026 14:22

Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2026, on March 16, 2026, MaxCyte, Inc. (the "Company") received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that, because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company did not comply with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1).

On June 10, 2026, the Company received a letter from Nasdaq, notifying the Company that the staff of Nasdaq has determined that for the last 10 consecutive business days, from May 27, 2026 to June 9, 2026, the closing bid price of the Company's common stock has been at $1.00 or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1), and the matter is now closed.

MaxCyte Inc. published this content on June 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 16, 2026 at 20:22 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]